Bank of New York Mellon Corp Lowers Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Bank of New York Mellon Corp lowered its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 0.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 281,943 shares of the company’s stock after selling 2,671 shares during the quarter. Bank of New York Mellon Corp owned 0.27% of Intellia Therapeutics worth $2,005,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in NTLA. Vanguard Group Inc. raised its stake in Intellia Therapeutics by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company’s stock valued at $118,816,000 after purchasing an additional 562,249 shares during the last quarter. Geode Capital Management LLC lifted its position in Intellia Therapeutics by 2.0% during the 4th quarter. Geode Capital Management LLC now owns 2,389,240 shares of the company’s stock worth $27,865,000 after acquiring an additional 45,930 shares in the last quarter. Two Sigma Advisers LP lifted its position in Intellia Therapeutics by 94.5% during the 4th quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company’s stock worth $23,300,000 after acquiring an additional 970,700 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Intellia Therapeutics by 36.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,976,212 shares of the company’s stock valued at $23,042,000 after purchasing an additional 528,962 shares in the last quarter. Finally, Two Sigma Investments LP raised its position in shares of Intellia Therapeutics by 88.1% in the 4th quarter. Two Sigma Investments LP now owns 1,843,743 shares of the company’s stock valued at $21,498,000 after purchasing an additional 863,363 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Insider Buying and Selling

In other Intellia Therapeutics news, EVP Edward J. Dulac III sold 7,462 shares of the firm’s stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $14.02, for a total value of $104,617.24. Following the completion of the sale, the executive vice president directly owned 106,062 shares of the company’s stock, valued at $1,486,989.24. This trade represents a 6.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders sold 12,534 shares of company stock worth $153,837 in the last 90 days. Company insiders own 3.10% of the company’s stock.

Intellia Therapeutics Stock Performance

Shares of NASDAQ:NTLA opened at $13.11 on Tuesday. The business’s 50 day simple moving average is $10.05 and its two-hundred day simple moving average is $9.38. The firm has a market cap of $1.36 billion, a P/E ratio of -2.51 and a beta of 2.21. Intellia Therapeutics, Inc. has a 52-week low of $5.90 and a 52-week high of $27.27.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.16. Intellia Therapeutics had a negative return on equity of 56.06% and a negative net margin of 1,154.10%. The company had revenue of $16.63 million for the quarter, compared to analyst estimates of $11.39 million. During the same quarter last year, the company earned ($1.12) earnings per share. The company’s revenue for the quarter was down 42.6% on a year-over-year basis. On average, equities analysts forecast that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on NTLA shares. Guggenheim dropped their price target on Intellia Therapeutics from $55.00 to $45.00 and set a “buy” rating on the stock in a research report on Monday, May 12th. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 16th. Citigroup decreased their target price on Intellia Therapeutics from $14.00 to $10.00 and set a “neutral” rating for the company in a research note on Friday, May 9th. Wolfe Research raised Intellia Therapeutics from a “peer perform” rating to an “outperform” rating and set a $21.00 target price for the company in a report on Monday, April 21st. Finally, Chardan Capital reaffirmed a “buy” rating and set a $68.00 target price on shares of Intellia Therapeutics in a report on Friday, May 9th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Intellia Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $33.37.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.